STOCK TITAN

Day One to Present at the 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

On January 5, 2022, Day One Biopharmaceuticals (Nasdaq: DAWN) announced that CEO Dr. Jeremy Bender will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11 at 10:30 a.m. ET. The presentation will be accessible via a live audio webcast on the company's website, with a replay available for 30 days afterwards. Day One is focused on developing targeted therapies for life-threatening diseases, including its lead candidate DAY101, currently in a pivotal Phase 2 trial for pediatric low-grade glioma.

Positive
  • None.
Negative
  • None.

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr. Jeremy Bender, chief executive officer, will present virtually during the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11 at 10:30 a.m. ET.

A live audio webcast of the presentation will be available by visiting the Events & Presentations section of the Company’s website. An archived replay of the webcast will be available for 30 days following the live presentation.

About Day One Biopharmaceuticals
Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases. Day One partners with leading clinicians, families, and scientists to identify, acquire, and develop important emerging targeted treatments. The Company’s lead product candidate, DAY101 (tovorafenib), is an oral, highly-selective type II pan-RAF kinase inhibitor currently being evaluated in a pivotal Phase 2 clinical trial (FIREFLY-1) in pediatric, adolescent and young adult patients with recurrent or progressive low-grade glioma (pLGG). The Company’s pipeline also includes the investigational agent pimasertib, a clinical-stage, oral, small molecule found to selectively inhibit mitogen-activated protein kinases 1 and 2 (MEK) will be evaluated in a Phase 1/2 study (FIRELIGHT-1) in combination with DAY101 for adult and adolescent patients with solid tumors with MAPK pathway aberrations. Day One is based in South San Francisco. For more information, please visit www.dayonebio.com or visit us on LinkedIn or Twitter.

Contacts:

Media:
1AB
Dan Budwick
dan@1abmedia.com

Investors:
LifeSci Advisors
Hans Vitzthum
hans@lifesciadvisors.com


FAQ

When is Day One Biopharmaceuticals presenting at the J.P. Morgan Healthcare Conference?

Day One Biopharmaceuticals will present on January 11, 2022, at 10:30 a.m. ET.

How can I access the Day One Biopharmaceuticals presentation?

The presentation will be available via a live audio webcast on the company's website.

What is the focus of Day One Biopharmaceuticals?

Day One Biopharmaceuticals is dedicated to developing targeted therapies for people with life-threatening diseases.

What is DAY101, the lead product candidate of Day One Biopharmaceuticals?

DAY101 (tovorafenib) is an oral, highly-selective type II pan-RAF kinase inhibitor in a pivotal Phase 2 trial for low-grade glioma.

Is there a replay available for the Day One Biopharmaceuticals presentation?

Yes, an archived replay of the webcast will be available for 30 days following the live presentation.

Day One Biopharmaceuticals, Inc.

NASDAQ:DAWN

DAWN Rankings

DAWN Latest News

DAWN Stock Data

1.35B
83.00M
16.98%
93.17%
17.87%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BRISBANE